Sari Pesonen

Sari Pesonen, Chief Scientific Officer (PhD, co-founder), has held scientific leadership roles in immuno-oncology biotech companies and has vast experience in clinical drug development. She joined Oncos Therapeutics as a Research Director and later took on the role of Head of Clinical Science, leading clinical sample analysis, which for the first time demonstrated the mode of action of oncolytic adenovirus-based cancer immunotherapy. Later, Sari worked as VP Preclinical Research and Clinical Science at Targovax. Sari gained her PhD in biology from the University of Turku, Finland in 2007. She continued her academic career at the University of Helsinki in a research group focusing on the development of oncolytic viruses for the treatment of cancer. She has supervised 3 PhD students and is a co-author on 60 peer-reviewed research papers.